In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents

Antimicrob Agents Chemother. 2024 May 2;68(5):e0136323. doi: 10.1128/aac.01363-23. Epub 2024 Mar 25.

Abstract

We subjected seven P. aeruginosa isolates to a 10-day serial passaging against five antipseudomonal agents to evaluate resistance levels post-exposure and putative resistance mechanisms in terminal mutants were analyzed by whole-genome sequencing analysis. Meropenem (mean, 38-fold increase), cefepime (14.4-fold), and piperacillin-tazobactam (52.9-fold) terminal mutants displayed high minimum inhibitory concentration (MIC) values compared to those obtained after exposure to ceftolozane-tazobactam (11.4-fold) and ceftazidime-avibactam (5.7-fold). Fewer isolates developed elevated MIC values for other β-lactams and agents belonging to other classes when exposed to meropenem in comparison to other agents. Alterations in nalC and nalD, involved in the upregulation of the efflux pump system MexAB-OprM, were common and observed more frequently in isolates exposed to ceftazidime-avibactam and meropenem. These alterations, along with ones in mexR and amrR, provided resistance to most β-lactams and levofloxacin but not imipenem. The second most common gene altered was mpl, which is involved in the recycling of the cell wall peptidoglycan. These alterations were mainly noted in isolates exposed to ceftolozane-tazobactam and piperacillin-tazobactam but also in one cefepime-exposed isolate. Alterations in other genes known to be involved in β-lactam resistance (ftsI, oprD, phoP, pepA, and cplA) and multiple genes involved in lipopolysaccharide biosynthesis were also present. The data generated here suggest that there is a difference in the mechanisms selected for high-level resistance between newer β-lactam/β-lactamase inhibitor combinations and older agents. Nevertheless, the isolates exposed to all agents displayed elevated MIC values for other β-lactams (except imipenem) and quinolones tested mainly due to alterations in the MexAB-OprM regulators that extrude these agents.

Keywords: P. aeruginosa; mutations; β-lactams.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Azabicyclo Compounds* / pharmacology
  • Cefepime / pharmacology
  • Ceftazidime* / pharmacology
  • Cephalosporins / pharmacology
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial / genetics
  • Humans
  • Meropenem* / pharmacology
  • Microbial Sensitivity Tests*
  • Piperacillin / pharmacology
  • Piperacillin, Tazobactam Drug Combination* / pharmacology
  • Pseudomonas aeruginosa* / drug effects
  • Pseudomonas aeruginosa* / genetics
  • Tazobactam* / pharmacology
  • Whole Genome Sequencing
  • beta-Lactamase Inhibitors* / pharmacology
  • beta-Lactams* / pharmacology

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • Azabicyclo Compounds
  • Meropenem
  • Tazobactam
  • Ceftazidime
  • avibactam, ceftazidime drug combination
  • beta-Lactams
  • Piperacillin, Tazobactam Drug Combination
  • Drug Combinations
  • Cephalosporins
  • Cefepime
  • ceftolozane, tazobactam drug combination
  • Piperacillin